Since the high mobility group box-1 (HMGB1) molecule had been recognized as a proinflammatory cytokine, which mediates endotoxin lethality of mice, there have been lots of papers about targeting the HMGB1 within the contexts of infection, inflammation, and cancer. The pathogenic impact of HMGB1 to the severe acute respiratory syndrome (SARS) and disease management with herbal formulations targeting this unique protein have already been proposed. However, the failure of the numerous current anti-viral therapies on the ongoing viral infections casts reappraisal of the possible interrelationships regarding the HMGB1 and SARS-CoV-2. COVID-19 pandemic due to the SARS-CoV-2 virus is a currently ongoing challenging global health crisis. There is still not any proven exact treatment of COVID-19 with high level of evidence. In this paper, we focused on the potential usage of external and/or inhalation preparation of antiviral/antibacterial herbal products capable of targeting HMGB1 for the clinical management candidates of the ongoing COVID-19 infection.

由于高迁移率族box-1（HMGB1）分子被认为是介导小鼠内毒素致死性的促炎性细胞因子，因此有许多关于在感染，炎症和癌症的背景下靶向HMGB1的论文。HMGB1对严重急性呼吸系统综合症（SARS）的致病作用和针对这种独特蛋白质的草药制剂的疾病管理已被提出。但是，当前针对正在进行的病毒感染的众多抗病毒疗法的失败使人们重新评估了关于HMGB1和SARS-CoV-2的可能相互关系。SARS-CoV-2病毒引起的COVID-19大流行是当前持续的具有挑战性的全球健康危机。仍没有任何证据证明高水平的COVID-19确切治疗。在本文中，